CN101273024A - 新颖苯并[d][1,3]-二氧杂环戊烯衍生物 - Google Patents

新颖苯并[d][1,3]-二氧杂环戊烯衍生物 Download PDF

Info

Publication number
CN101273024A
CN101273024A CNA2006800351923A CN200680035192A CN101273024A CN 101273024 A CN101273024 A CN 101273024A CN A2006800351923 A CNA2006800351923 A CN A2006800351923A CN 200680035192 A CN200680035192 A CN 200680035192A CN 101273024 A CN101273024 A CN 101273024A
Authority
CN
China
Prior art keywords
compound
deuterium
prodrug
disorder
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800351923A
Other languages
English (en)
Chinese (zh)
Inventor
R·通
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of CN101273024A publication Critical patent/CN101273024A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
CNA2006800351923A 2005-07-29 2006-07-28 新颖苯并[d][1,3]-二氧杂环戊烯衍生物 Pending CN101273024A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70407305P 2005-07-29 2005-07-29
US60/704,073 2005-07-29

Publications (1)

Publication Number Publication Date
CN101273024A true CN101273024A (zh) 2008-09-24

Family

ID=37709249

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800351923A Pending CN101273024A (zh) 2005-07-29 2006-07-28 新颖苯并[d][1,3]-二氧杂环戊烯衍生物

Country Status (12)

Country Link
US (5) US20080287495A1 (enExample)
EP (1) EP1910322B1 (enExample)
JP (1) JP5301991B2 (enExample)
KR (1) KR101380190B1 (enExample)
CN (1) CN101273024A (enExample)
AU (1) AU2006275595B2 (enExample)
BR (1) BRPI0615973A2 (enExample)
CA (1) CA2616383C (enExample)
EA (1) EA014432B1 (enExample)
ES (1) ES2396365T3 (enExample)
WO (1) WO2007016431A2 (enExample)
ZA (1) ZA200800785B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245613A (zh) * 2008-10-13 2011-11-16 詹森药业有限公司 苯基和杂芳基取代的噻吩并[2，3-d]嘧啶及它们作为腺苷A2a受体拮抗剂的用途
CN104039777A (zh) * 2012-01-31 2014-09-10 卫材R&D管理有限公司 帕罗西汀衍生物
CN105324376A (zh) * 2013-06-27 2016-02-10 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途
US9896423B2 (en) 2014-05-30 2018-02-20 Jiangsu Jibeier Pharmaceutical Co., Ltd. Deuterium substituted 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine compound or derivatives thereof, and pharmaceutical composition and use thereof
CN107970243A (zh) * 2017-10-30 2018-05-01 江苏理工学院 一种去甲氯氮平的新用途
CN109134432A (zh) * 2017-06-15 2019-01-04 泰州华元医药科技有限公司 氘代抗抑郁药物
CN110283156A (zh) * 2019-07-29 2019-09-27 河北省农林科学院经济作物研究所 从刺五加中提取的新型降血脂化合物

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CN101460461B (zh) * 2006-04-03 2012-10-03 弗·哈夫曼-拉罗切有限公司 对映体富集的环β-芳基或杂芳基羧酸的制备方法
US20080139563A1 (en) * 2006-10-23 2008-06-12 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
ATE509015T1 (de) * 2007-03-07 2011-05-15 Concert Pharmaceuticals Inc Deuterierte piperazinderivate als verbindungen gegen angina
CA2685924A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl)acetamides
PT2357183E (pt) 2007-05-01 2015-09-28 Concert Pharmaceuticals Inc Compostos de morfinano
EP2522667B1 (en) * 2007-05-01 2014-08-20 Concert Pharmaceuticals Inc. Morphinan compounds
JP2010529994A (ja) * 2007-06-13 2010-09-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピペラジン
JP5647519B2 (ja) * 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
MX2011000637A (es) * 2008-07-15 2011-05-02 Theracos Inc Derivados deuretados de bencilbenceno y metodos de uso.
WO2010010141A1 (en) * 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Pramipexole for treating cardiomyopathy
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EA201391720A1 (ru) * 2008-11-14 2014-04-30 Консерт Фармасьютикалс Инк. Замещенные диоксопиперидинилфталимидные производные
US20100143505A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Indanone inhibitors of acetylcholinesterase
WO2010075086A2 (en) * 2008-12-15 2010-07-01 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
SG10201406839VA (en) * 2009-10-26 2014-12-30 Otsuka Pharma Co Ltd Benzazepine compound
WO2011159920A1 (en) * 2010-06-17 2011-12-22 Concert Pharmaceuticals, Inc. [5,6]-dihydro-2h-pyran-2-one derivatives
ME02513B (me) 2011-06-20 2017-02-20 H Lundbeck As Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije
EP2847203A1 (en) 2012-02-03 2015-03-18 Selectx Pharmaceuticals, Inc. 4,6-substituted 2,5-dideoxystreptamine aminoglycoside antibiotics
EP2687854A1 (en) * 2012-07-19 2014-01-22 Chiron AS Test kit for the quantitative determination of narcotic drugs
US9643950B2 (en) 2012-10-22 2017-05-09 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
RU2019104092A (ru) 2013-03-13 2019-03-20 Бостон Байомедикал, Инк. Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака
AU2015296098B2 (en) 2014-07-29 2019-06-27 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
US10037449B1 (en) 2015-09-29 2018-07-31 Amazon Technologies, Inc. Inventory tracking using RFID
US10089505B1 (en) 2015-09-29 2018-10-02 Amazon Technologies, Inc. Inventory tracking using RFID
WO2017191599A1 (en) 2016-05-04 2017-11-09 Genoscience Pharma Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
EP3456328A4 (en) 2016-05-10 2020-02-26 Shenzhen Hightide Biopharmaceutical., Ltd. Composition, and application and pharmaceutical preparation thereof
MX2018015452A (es) 2016-12-15 2020-02-10 Soc Des Produits Nestle S A Star Composiciones y metodos que modulan fosforo o las enzimas en un aminal de compañia.
CN108864077B (zh) 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法
CN111683662B (zh) 2017-08-28 2024-04-02 陈志宏 取代嘧啶类化合物及其药物组合物和治疗方法
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
CN113396150B (zh) 2018-11-01 2024-03-12 凌科药业(杭州)有限公司 三环janus激酶1抑制剂及其组合物和方法
JP7583719B2 (ja) 2018-12-03 2024-11-14 ハー・ルンドベック・アクチエゼルスカベット ４－（（１Ｒ，３Ｓ）－６－クロロ－３－フェニル－２，３－ジヒドロ－１Ｈ－インデン－１－イル）－１，２，２－トリメチルピペラジン及び４－（（１Ｒ，３Ｓ）－６－クロロ－３－（フェニル－ｄ５）－２，３－ジヒドロ－１Ｈ－インデン－１－イル）－２，２－ジメチル－１－（メチル－ｄ３）ピペラジンのプロドラッグ
WO2020146845A1 (en) 2019-01-11 2020-07-16 University Of Rochester Compositions and methods for treating prostate cancer with enzalutamide and an inhibitor of monoamin oxidase a
CN117462549A (zh) 2019-02-01 2024-01-30 康威(广州)生物科技有限公司 咪唑并喹啉胺衍生物、及其药物组合物和应用
CN114616234B (zh) 2019-02-07 2024-04-12 康威(广州)生物科技有限公司 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
JP2022550851A (ja) 2019-10-04 2022-12-05 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
US20230340491A1 (en) 2020-04-22 2023-10-26 University Of Rochester Compositions and methods for treating metabolic and cardiovascular diseases
JP2022100060A (ja) * 2020-12-23 2022-07-05 大陽日酸株式会社 モノ重水素化ジハロゲン化メタン、重水素化シクロプロパン化合物及びそれらの製造方法
JP2024506999A (ja) 2021-02-02 2024-02-15 コン，ヤンピン がんを処置するための組成物および方法
AU2022297453A1 (en) 2021-06-22 2024-01-04 Crimson Biopharm Inc. (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors
WO2025126109A1 (en) 2023-12-15 2025-06-19 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0335918A1 (en) * 1987-08-07 1989-10-11 Mallinckrodt Diagnostica (Holland) B.V. Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound
CA2186371A1 (en) * 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
SK283394B6 (sk) * 1997-06-10 2003-07-01 Synthon B. V. Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
JP5647519B2 (ja) * 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245613A (zh) * 2008-10-13 2011-11-16 詹森药业有限公司 苯基和杂芳基取代的噻吩并[2，3-d]嘧啶及它们作为腺苷A2a受体拮抗剂的用途
CN104039777A (zh) * 2012-01-31 2014-09-10 卫材R&D管理有限公司 帕罗西汀衍生物
CN104039777B (zh) * 2012-01-31 2016-03-02 卫材R&D管理有限公司 帕罗西汀衍生物
CN105324376A (zh) * 2013-06-27 2016-02-10 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途
US9896423B2 (en) 2014-05-30 2018-02-20 Jiangsu Jibeier Pharmaceutical Co., Ltd. Deuterium substituted 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine compound or derivatives thereof, and pharmaceutical composition and use thereof
CN109134432A (zh) * 2017-06-15 2019-01-04 泰州华元医药科技有限公司 氘代抗抑郁药物
CN109134432B (zh) * 2017-06-15 2021-06-11 北京君科华元医药科技有限公司 氘代抗抑郁药物
CN107970243A (zh) * 2017-10-30 2018-05-01 江苏理工学院 一种去甲氯氮平的新用途
WO2019085827A1 (zh) * 2017-10-30 2019-05-09 江苏理工学院 一种去甲氯氮平的新用途
KR20200059209A (ko) * 2017-10-30 2020-05-28 지앙수 유니버시티 오브 테크놀로지 데스메틸클로자핀의 새로운 용도
CN107970243B (zh) * 2017-10-30 2020-07-28 江苏理工学院 一种去甲氯氮平的新用途
KR102401604B1 (ko) 2017-10-30 2022-05-24 지앙수 유니버시티 오브 테크놀로지 데스메틸클로자핀의 새로운 용도
CN110283156A (zh) * 2019-07-29 2019-09-27 河北省农林科学院经济作物研究所 从刺五加中提取的新型降血脂化合物
CN110283156B (zh) * 2019-07-29 2020-06-30 河北省农林科学院经济作物研究所 从刺五加中提取的新型降血脂化合物

Also Published As

Publication number Publication date
AU2006275595A1 (en) 2007-02-08
JP5301991B2 (ja) 2013-09-25
AU2006275595B2 (en) 2012-08-16
HK1117532A1 (en) 2009-01-16
KR101380190B1 (ko) 2014-04-11
EA014432B1 (ru) 2010-12-30
US7678914B2 (en) 2010-03-16
JP2009502963A (ja) 2009-01-29
CA2616383C (en) 2015-06-09
WO2007016431A2 (en) 2007-02-08
US20070191432A1 (en) 2007-08-16
ES2396365T3 (es) 2013-02-21
EP1910322B1 (en) 2012-09-05
BRPI0615973A2 (pt) 2011-05-31
ZA200800785B (en) 2009-01-28
WO2007016431A3 (en) 2007-07-12
US20140018390A1 (en) 2014-01-16
US8450492B2 (en) 2013-05-28
CA2616383A1 (en) 2007-02-08
EP1910322A2 (en) 2008-04-16
KR20080039949A (ko) 2008-05-07
US20100222589A1 (en) 2010-09-02
US20150196544A1 (en) 2015-07-16
EP1910322A4 (en) 2010-09-22
US20080287495A1 (en) 2008-11-20
EA200800490A1 (ru) 2008-08-29

Similar Documents

Publication Publication Date Title
CN101273024A (zh) 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
US20080033011A1 (en) Novel benzo[d][1,3]-dioxol derivatives
US7863274B2 (en) Deuterium enriched analogues of tadalafil as PDE5 inhibitors
JP5647519B2 (ja) 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
KR20080047375A (ko) 약제 화합물
KR20050084540A (ko) 신규 화합물을 포함하는 제약 조성물
WO2010028130A2 (en) Antidepressant compounds
HK1117532B (en) Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors
EP0699676B1 (en) Physical form of dihidro-2,3-benzodiazepine derivative
JP4566749B2 (ja) ３−（シクロペンテン−１−イル）−ベンジル−または３−（シクロペンテン−１−イル）−ヘテロアリールメチルアミン誘導体および統合失調症を治療するための医薬としてのそれらの使用
CN101277613A (zh) 新颖医药化合物
US20030083338A1 (en) Compositions and methods for management of serotonin-mediated disorders
HK1013819B (en) Physical form of dihidro-2,3-benzodiazepine derivative
HK1013820A1 (en) Crystalline form of dihydro-2,3-benzodiazepine derivative
HK1013820B (en) Crystalline form of dihydro-2,3-benzodiazepine derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080924